Gossamer Bio (GOSS) Accounts Payables (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Accounts Payables of $10.8 million for Q1 2026, up 219.33% year-over-year from $3.4 million in Q1 2025, and up 81.61% quarter-over-quarter from $6.0 million in Q4 2025.
Gossamer Bio (GOSS) Accounts Payables (2018 - 2026) Analysis & Trends
Gossamer Bio's Accounts Payables history runs 9 years deep, the most recent figure standing at $10.8 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 219.33% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (up 219.33% YoY), while the FY2025 annual figure was $6.0 million, up 156.96% from the prior year.
- Accounts Payables for Q1 2026 stood at $10.8 million, up from $6.0 million in the prior quarter.
- The five-year high for Accounts Payables was $10.8 million in Q1 2026, with the low at $363000.0 in Q3 2022.
- The 5-year median for Accounts Payables is $2.3 million (2024), against an average of $3.0 million.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables slumped 69.37% in 2022, then jumped 361.32% in 2023.
- Gossamer Bio's Accounts Payables stood at $1.5 million in 2022, then surged by 278.75% to $5.5 million in 2023, then plunged by 58.03% to $2.3 million in 2024, then jumped by 156.96% to $6.0 million in 2025, then soared by 81.61% to $10.8 million in 2026.
- Business Quant data shows GOSS's Accounts Payables at $10.8 million in Q1 2026, $6.0 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | 5.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.95 Mn |
| Mar 31, 2026 | 10.82 Mn |
| Dec 31, 2025 | 5.96 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.88 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 5.53 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 2.73 Mn |
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 363,000.00 |
| Jun 30, 2022 | 3.91 Mn |
| Mar 31, 2022 | 592,000.00 |
| Dec 31, 2021 | 3.24 Mn |
| Sep 30, 2021 | 1.19 Mn |